Multiple Myeloma Clinical Trials

168 studies are recruiting for multiple myeloma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 5

1. Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

   The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant [ASCT]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC) Daratumumab. The ma…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   2 in total

   Run by

   Barbara Ann Karmanos Cancer Institute

   See if you can join NCT06107738 on ClinicalTrials.gov

2. Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

   This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVH…

   Stage

   Phase 2

   Ages

   Up to 60

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT03314974 on ClinicalTrials.gov

3. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

   A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory Winship Cancer Institute, Atlanta, Georgia

   Locations

   39 in total

   Run by

   CellCentric Ltd.

   See if you can join NCT04068597 on ClinicalTrials.gov

4. A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

   The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07454382 on ClinicalTrials.gov

5. Personalized Autologous Transplant for Multiple Myeloma

   This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them fr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Winship Cancer Institute of Emory University, Atlanta, Georgia

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT04483206 on ClinicalTrials.gov

6. The Ambient Light Multiple Myeloma Study

   The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multi…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Icahn Schoool of Medicine at Mount Sinai, New York, New York

   Locations

   2 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT05737732 on ClinicalTrials.gov

7. Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

   A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT05405387 on ClinicalTrials.gov

8. Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

   This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Iowa Health Care, Iowa City, Iowa

   Run by

   Christopher Strouse

   See if you can join NCT07581704 on ClinicalTrials.gov

9. Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

   This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

   Locations

   5 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT05145400 on ClinicalTrials.gov

10. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

    This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California Los Angeles (UCLA), Los Angeles, California

    Locations

    32 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05828511 on ClinicalTrials.gov

11. Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

    Multiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis than those with MRD negative disease. Bispecific T-cell-based immunot…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Yale University, New Haven, Connecticut

    Locations

    2 in total

    Run by

    Noffar Bar

    See if you can join NCT06993675 on ClinicalTrials.gov

12. Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adul…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center /ID# 266921, Beverly Hills, California

    Locations

    27 in total

    Run by

    AbbVie

    See if you can join NCT06896916 on ClinicalTrials.gov

13. DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

    This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma. The names of the study drugs involved in this study are: …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Run by

    David Avigan

    See if you can join NCT07377435 on ClinicalTrials.gov

14. A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

    This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM). The names of the study drugs and vaccine involved in this study are: * DC/MM …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    2 in total

    Run by

    David Avigan

    See if you can join NCT06799026 on ClinicalTrials.gov

15. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

    Stage

    Phase 1

    Ages

    13 and older

    Site

    University of Chicago, Chicago, Illinois

    Locations

    8 in total

    Run by

    Newave Pharmaceutical Inc

    See if you can join NCT04771572 on ClinicalTrials.gov

16. A Dietary Study for People With Multiple Myeloma

    The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd)…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07226609 on ClinicalTrials.gov

17. FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

    The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma precursor disease or newly diagnosed multiple myeloma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT07446777 on ClinicalTrials.gov

18. Post-Op Pain Control for Prophylactic Intramedullary Nailing.

    Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to NSAID use. Orthopedic oncology, however, has a uni…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Saint Louis University, St Louis, Missouri

    Run by

    St. Louis University

    See if you can join NCT03823534 on ClinicalTrials.gov

19. Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

    This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Arizona Oncology Associates, Tucson, Arizona

    Locations

    17 in total

    Run by

    SCRI Development Innovations, LLC

    See if you can join NCT05972135 on ClinicalTrials.gov

20. A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

    The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    GSK Investigational Site, Mobile, Alabama

    Locations

    181 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT06679101 on ClinicalTrials.gov

21. Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

    The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be rando…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital Cancer Center, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05646576 on ClinicalTrials.gov

22. At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

    This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Locations

    2 in total

    Run by

    Mayo Clinic

    See if you can join NCT05969860 on ClinicalTrials.gov

23. The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

    To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.

    Stage

    Not phased

    Ages

    18 to 120

    Site

    Wake Forest Baptist Health, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT01890486 on ClinicalTrials.gov

24. Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

    This clinical trial tests the effectiveness of a home-based mindfulness physical activity program with remote monitoring combined with structured telephone-based health coaching to decrease fatigue and improve quality of life in older patients with multiple myeloma (MM). Studies have shown that MM …

    Stage

    Not phased

    Ages

    65 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06145581 on ClinicalTrials.gov

25. Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

    The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Miami Hospitals, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT05361694 on ClinicalTrials.gov